Pediatric Sepsis by Multi-Drugs Resistance Organism: Length of Stay, Prognosis, and Hospitalization Cost Evaluation

Authors

  • Anindita Novia Damayanti Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital
  • IGAA Putri Sri Rejeki Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital
  • Ferdy Royland Marpaung Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital

DOI:

https://doi.org/10.24293/ijcpml.v28i2.1711

Keywords:

MDR, ESBL, LOS, BPJS

Abstract

Multi-Drugs Resistance (MDR) is a condition where bacteria are resistant to at least one type of antibiotic from three classes of antibiotics. One of the organisms included in the MDR is an Extended-Spectrum Beta Lactamase (ESBL) producing bacteria. Multi-drug resistance bacteria have been widely reported globally as a cause of severe infections. Still, information on the comparison of Length of Stay (LOS), hospitalization costs, and outcome status of the patients infected with MDR bacteria and infected with non-MDR bacteria is still limited. This study aimed to compare LOS, treatment costs, and outcome status of the BPJS pediatric sepsis patients infected with MDR bacteria and non-MDR bacteria in Dr. Soetomo General Academic Hospital, Surabaya. This study was observational research using medical records of hospitalized pediatric patients with BPJS insurance at the Dr. Soetomo General Academic Hospital from January 2015-July 2018 (n=49). The variables of this study were microbiology culture results and antibiotics sensitivity tests, LOS, INA-CBGs rates provided by BPJS, actual hospitalization cost, and outcome status. Statistical analyses were performed to compare LOS, INA-CBGs, actual cost, and outcome status of patients infected by MDR bacteria (ESBL and non-ESBL) or non-MDR bacteria. The results of this study include the average LOS value of non-MDR, MDR ESBL, and MDR non-ESBL cases, which were 30.55; 46.18; 32.41. Comparison of INA-CBGs and the actual cost of the three were 0.886 and 0.990, respectively, with p>0.05, and each percentage of the mortality patients was 27.3%, 45.5%, and 40.7%. There was no significant difference in the hospitalization cost and outcome status of patients infected by MDR bacteria (ESBL and non-ESBL) and non-MDR bacteria. Each percentage of LOS was also not much different. Still, MDR patients tended to be treated longer, require higher costs, and have a worse
prognosis.

Downloads

Download data is not yet available.

Author Biographies

Anindita Novia Damayanti, Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital

Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital

IGAA Putri Sri Rejeki, Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital

Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital

Ferdy Royland Marpaung, Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital

Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital

References

Nikaido H. Multidrug resistance in bBacteria. Annu Rev Biochem, 2009; 78: 119-146.

ITKI. Rawat Inap RSUD Dr. Soetomo. 2018. Available at: http://rsudrsoetomo.jatimprov.go.id/rawat-inap/

Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a Clinical update. Clinical microbiology review: American Society for Microbiology, 2005; 657-686.

Roberts RR, Hota B, Ahmad I, Scott RD II, Foster SD, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: Implications for antibiotic stewardship. Clin. Infect. Dis, 2009; 49: 1175-84.

Melvin PW, et al. Performance standards for antimicrobial susceptibility testing: Clinical and Laboratory Standards Institute (CLSI) 28. 2018; 242-246.

WHO. International Classification of Diseases (ICD) – 10 Version 2016. Centers for Medicare and Medicaid Services – CMS. Available at: http://www.who.int>classifications

ClinMicro.orgBlog. Extended spectrum beta lactamases: A review. 2011. Available from: http://www.clinmicro.org/blog/?p=21

Frieden T. Antibiotic resistance and the threat to public health. Centers for Disease Control and Prevention (CDC). 2010.

Xiao T, Wu Z, Shi Q, Zhang X, Zhou Y, et al. A Retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Eschericia coli bloodstream infections. Journal of Global Antimicrobial Resistance, 2019; 147-156.

Downloads

Submitted

2020-10-14

Accepted

2022-01-06

Published

2022-06-03

How to Cite

[1]
Damayanti, A.N., Sri Rejeki, I.P. and Marpaung, F.R. 2022. Pediatric Sepsis by Multi-Drugs Resistance Organism: Length of Stay, Prognosis, and Hospitalization Cost Evaluation. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 28, 2 (Jun. 2022), 165–169. DOI:https://doi.org/10.24293/ijcpml.v28i2.1711.

Issue

Section

Articles